Highlights, including post period:
- Data Safety Monitoring Board review supported dose escalation in Ph 1b and initiation of Ph2a
-
Site activation of Ph2a in US and
Europe proceeding well -
Bemcentinib remains the leading selective AXL inhibitor in the clinic and was selected for inclusion in
National Cancer Institute funded study in advanced NSCLC, led by theMays Cancer Center at theUniversity of Texas Health Science Center at San Antonio -
Financial position of
NOK 117.3 million at 31 March - strengthened further with gross funding ofNOK 138.9 million from warrants exercise inApril 2024
-
Continued reduction of operating expenses from
NOK 72.4 million in Q1 2023 toNOK 39.9 million in Q1 2024 -
Net cash flow of
NOK -42.5 million
"1L NSCLC STK11m patients are not currently eligible for targeted therapy and face a very poor prognosis. The total market for this patient group is estimated to be between 4 and
Presentation and Financial Report
The Q1 2024 Financial report is attached to this stock exchange announcement and the report and the Q1 2024 presentation are available at the Company's website https://www.bergenbio.com/investors/financial-reports.
Webcast details
https://channel.royalcast.com/landingpage/hegnarmedia/20240529_1/
A recording of the webcast will be available at www.bergenbio.com in the Investors/Financial Reports section (https://www.bergenbio.com/investors/financial-reports) shortly afterwards.
Contacts
ir@bergenbio.com
rune.skeie@bergenbio.com
Media Relations
jl@lillebyfrisch.no
About
Forward looking statements
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties, and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements.
This information is considered to be inside information pursuant to the EU Market Abuse Regulation and subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
https://news.cision.com/bergenbio-asa/r/bergenbio-first-quarter-results-2024--advancing-to-the-next-stage-of-development,c3990167
https://mb.cision.com/Public/15728/3990167/8bc13471fa9d40cf.pdf
(c) 2024 Cision. All rights reserved., source